

PUBLISHED BY PORTLAND PRESS ON BEHALF OF
THE MEDICAL RESEARCH SOCIETY AND THE BIOCHEMICAL SOCIETY

© The Medical Research Society and the Biochemical Society 1996
ISSN 0143-5221

*Typeset by Unicus Graphics Ltd, Horsham,
and printed in Great Britain by Bell and Bain Ltd, Glasgow*

ACKNOWLEDGMENTS

The Editorial Board of *Clinical Science* gratefully acknowledges the assistance given by the following referees during the year 1995.

- Abernathy, D.
Agardh, E.
Agrotis, A.
Aitkenhead, A.R.
Ali, N.
Andersen, D.
Anderson, S.
Andrews, F.
Angelin, B.
Araki, S.
Archard, L.
Ardawi, M.S.M.
Arieff, A.I.
Armstrong, V.W.
Arnold, J.M.O.
Arnqvist, H.
Arslanian, S.
Arthur, J.
Astarie Dequecker, C.
Bailey, R.R.
Baines, A.
Bankir, L.
Banks, R.
Barclay, R.
Baron, A.D.
Barradas, M.A.
Barrett, E.J.
Barton, H.
Basse, J.E.
Batchelard, H.
Beaudouin-Legros, M.
Beavan, L.
Beckett, G.
Bell, J.
Belpaire, F.
Benjamin, N.
Bennett, A.
Berl, T.
Berne, C.
Besley, G.
Best, J.
Beynon, H.
Bharaj, H.S.
Bhatnagar, D.
Bie, P.
Bishop, J.
Bistrián, B.R.
Black, C.
Blomberg, P.
Bobik, A.
Boer, W.H.
Bolter, C.P.
Bonham, J.
Bolton, C.
Boot-Handford, R.
Boughton-Smith, N.K.
Boulanger, C.
Bowyer, D.E.
Brain, S.D.
Brands, M.
Brasseur, D.
Breyer, M.D.
Bringham, F.R.
Britton, K.E.
Brodie, D.
Brown, M.A.
Bryer-Ash, M.
Bund, S.
Burdett, K.
Burdon, R.H.
Burgess, A.W.
Burrell, L.M.
Calder, P.C.
Calver, A.
Cameron, N.E.
Campbell, E.
Caprio, S.
Carlson, M.G.
Caro, C.G.
Casadei, B.
Casolaro, A.
Charles, C.
Chau, N.P.
Cherniak, N.
Cherrington, A.
Ch'ng, J.L.C.
Chowienzyk, P.J.
Chung, K.F.
Clapp, J.
Clarke, C.
Clavey, V.
Clayton, P.
Cleland, J.
Clement, D.L.
Cline, G.
Cockcroft, J.R.
Cole, A.T.
Collins, A.
Collins, P.
Cooke, J.P.
Crotty, B.
Crouch, M.
Cruikshank, J.K.
Cuspidi, C.
Dantzker, D.
Dart, T.
Davidson, N.
Davies, D.
Davies, M.
Dausse, J.P.
Day, C.P.
De Backer, G.
Deegan, P.C.
de Jong, N.
de Leeuw, P.W.
de Rijke, Y.B.
de Vernejoul, M.C.
Deutz, N.
Dimsdale, J.E.
Dockray, G.J.
Donker, A.J.M.
Donnelly, S.
Doorly, D.
Dornhurst, A.
Dowling, D.
Dransfield, I.
Drejer, K.A.
Dryden, S.
Dullaart, R.P.F.
Duprez, D.
During, M.
Duthie, G.
Edelman, A.
Edelson, G.
Ec, H.
Elahi, D.
Elia, M.
Emery, P.W.
Emmerich, J.
Enholm, C.
Eriksen, E.F.
Eriksson, U.
Escourrou, P.
Esler, M.D.
Espiner, E.A.
Evans, B.
Fallen, E.
Fearon, K.
Feizi, T.
Feldman, R.
Fera, J.C.
Ferguson, A.
Fernig, D.
Ferrari, A.U.
Ferrari, M.D.
Feuvray, D.
Fitchett, D.
Ford, G.A.
Forster, C.
Forsling, M.
Forte, L.R.
Fosang, A.
Franceschini, G.
Frayn, K.N.
Freeman, D.
Freestone, S.
Frelin, C.
Friedman, P.
Fryburg, D.
Fuller, B.J.
Furst, P.
Garlick, P.
Gaultier, C.
Gefland, R.A.
Gellai, M.
Gibson, P.
Gilchrist, N.L.
Goode, G.K.
Goodlad, R.
Gore, M.
Gosden, C.M.
Goto, K.
Grassi, G.
Green, A.
Green, C.J.
Greenhaff, P.
Griffiths, R.
Griffiths, T.M.
Grimble, G.
Grimm, M.
Groop, L.
Grubeck-Loebenstein, B.
Haddy, F.
Hales, C.
Hales, J.
Hall, M.J.
Halliday, D.
Hans, G.
Hansen, P.R.
Hanson, U.
Harding, J.J.
Harris, K.
Head, G.A.
Heagerty, A.M.
Helft, G.
Henderson, I.S.
Hill, J.
Hjemdahl, P.
Holder, D.S.
Home, P.D.
Hother Nielsen, O.
Hughes, A.
Hughes, P.
Hughson, R.
Huisman, R.M.
Hultcrantz, R.
Hunter, J.
Ikeda, U.
Ikram, H.
Imazumi, T.
Ind, P.
Iouzalén, L.
Iredale, J.P.
Jack, C.I.A.
Jackson, M.J.
Jain, B.
Jakeman, P.M.
Janssen, W.M.T.
Jenkinson, S.
Jennings, G.L.
Jensen, M.
Johnson, M.R.
Johnston, P.W.
Johnstone, F.
Jones, D.
Jones, M.
Jover, B.
Julius, S.
Kamen, P.
Kaplan, A.
Khan, F.
Kingsnorth, A.N.
Kingwell, B.
Kinnear, W.
Klein, G.
Knox, A.
Knox, F.
Koomans, H.A.
Kopp, U.
Korner, P.
Kostuk, W.
Krediel, R.Th.

- L'Abbate, A.
 Lacolley, P.
 Lang, C.C.
 Langley-Evans,
 S.C.
 Lassen, N.A.
 Laszlo, G.
 Laurent, S.
 Lazarus, J.H.
 Lean, M.E.J.
 Ledet, T.
 Lennox, G.
 Leonard, R.C.F.
 Le Quan Sang,
 K.-H.
 Lerman, A.
 Lipworth, B.J.
 Lockwood, M.
 Lombard, M.
 Lombardi, F.
 London, G.
 Lowe, G.D.O.
 Luke, R.
 Lundholm, K.
 Lyall, F.
 Lydyard, P.M.

 Macallan, D.
 MacAllister, R.
 Macdonald, I.A.
 Macdonald, P.
 MacFadyen, R.J.
 Mackness, M.I.
 MacLenachan, J.
 MacNee, W.
 Maggs, D.
 Malik, R.
 Maling, T.J.B.
 Malluche, H.
 Manhem, K.
 Mann, S.
 Matthias, C.J.
 Maxwell, S.R.J.
 McClinton, S.
 McConnell, A.K.
 McGrath, B.
 McGuinness, O.
 McIntosh, R.S.
 McLaughlin, P.J.
 McLay, J.S.
 McLindon, J.P.
 McNally, P.

 Meneilly, G.S.
 Mikhailidis, D.
 Millar, J.A.
 Miller, J.P.
 Millward, D.J.
 Mimran, A.
 Mohanty, P.K.
 Mol, M.J.
 Moore, G.
 Moore, K.
 Morgan, M.Y.
 Morris, C.
 Morris, J.
 Morrison, J.
 Motwani, J.G.

 Naismith, D.J.
 Navis, G.J.
 Neary, R.H.
 Nemer, M.
 Nestel, P.
 Newham, D.J.
 Newton, G.
 Ng, L.L.
 Nicholls, M.G.
 Nilsson, H.
 Nisell, H.
 Norman, R.I.
 Novak, V.
 Nussberger, J.

 O'Brien, E.
 O'Callaghan, C.
 O'Connor, B.
 Ohanian, J.
 Olsen, N.V.
 O'Morain, C.A.
 O'Neill, G.
 O'Rourke, M.F.
 O'Saughnessy, K.
 Ouchi, Y.
 Owen, J.S.
 Owen, O.E.

 Pagani, M.
 Palatini, P.
 Pannier, B.
 Parati, G.
 Pare P.
 Parfitt, V.
 Parkes, D.
 Parving, H.-H.

 Patel, A.
 Paterson, C.
 Paul, S.
 Pavli, P.
 Pedersen, O.
 Pencharz, P.
 Perrella, M.
 Piquette, C.
 Pomfrett, C.J.D.
 Por, J.N.
 Poston, L.
 Powell-Tuck, J.
 Preedy, V.
 Preuss, H.G.
 Price, R.G.
 Provoost, A.P.

 Rabelink, A.
 Rampton, D.S.
 Reckelhoff, J.F.
 Reeds, P.
 Reid, J.
 Rennie, M.J.
 Rérat, A.
 Rhodes, J.M.
 Rhodes, P.
 Rice-Evans, C.
 Richard, V.
 Riesen, W.F.
 Riis Hansen, R.
 Rippe, B.
 Robbins, R.
 Rodger, S.
 Romero, J.C.
 Ruddy, T.D.
 Russell, D.
 Russell, F.D.
 Rutherford, O.
 Ryder, S.

 Sagnella, G.A.
 Sainsbury, R.
 Sands, J.M.
 Saruta, T.
 Saul, J.P.
 Scherrer, U.
 Schiffrin, E.L.
 Schmieder, R.E.
 Schofield, G.G.
 Schuppan, D.
 Schuyler, M.

 Schwarzer, A.P.
 Selby, W.
 Sever, P.
 Shenkin, A.
 Sheron, N.
 Shibayama, Y.
 Shiojima, I.
 Shiota, M.
 Shore, A.
 Silk, D.B.
 Silverman, M.
 Simmons, D.
 Singer, D.R.J.
 Skinner, S.L.
 Smit, A.A.J.
 Smyth, D.D.
 Soutar, A.
 Specchia, G.
 Spurr, N.
 Stalenhoeft, A.
 Stamp, T.
 Starr, J.M.
 Stjernström, H.
 Strauer, B.E.
 Strumpe, K.O.
 Svendsen, O.L.
 Sugden, M.
 Sundkvist, D.G.
 Suzuki, H.

 Takeda, K.
 Takizawa, H.
 Taskinen, M.-R.
 Tattersfield, A.
 Taubert, K.
 Taylor, J.
 Theodore, J.
 Thien, Th.
 Thompson, A.
 Thompson, A.H.
 Thorburn, A.
 Thuraingham, R.
 Tighe, R.
 Tomlinson, D.
 Tooke, J.E.
 Toska, K.
 Tunny, A.N.
 Turner, A.N.

 Vallance, P.
 van de Borne, P.

 van Lieshout, J.J.
 Van Rij, A.
 van Zwieten, P.A.
 Vanoli, E.
 Vassart, G.
 Vassort, G.
 Vaz, M.
 Verbolis, J.G.
 Vetter, H.
 Vos, P.
 Vyas, H.

 Wagenmakers, A.
 Wahren, J.
 Wallberg-
 Henrikson, H.
 Walker, R.
 Soutar, A.
 Ward, S.A.
 Wardland, A.J.
 Warren, P.M.
 Wastell, H.J.
 Watson, A.J.M.
 Watt, P.
 Weaver, L.
 Webb, D.J.
 Weinberger, M.
 Weise, F.
 Wernerman, J.
 West, M.
 Westerman, R.
 White, H.
 Whiting, P.
 Whyte, M.
 Wieling, W.
 Wilcox, J.N.
 Winocour, P.
 Wintour-Coghlan,
 M.
 Winwood, P.J.
 Woodside, B.

 Yanagisawa, M.
 Yandle, T.
 Yeaman, S.J.
 Yin, J.A.L.
 Young, V.

 Zhou, J.
 Zidek, W.
 Zimmerman, G.
 Zinman, B.

Volume 91

AUTHOR INDEX

- Abdel-Meguid, E. 187–191
Abdel-Tawab, S. 187–191
Abu-Amsha, R. 449–458
Aguilera, M.T. 155–161
Ainley, C. 219–223
Albert, J. 225–231
Allan, P.L. 17–21
Almada, A.L. 113–118
Amadi, A.A. 391–398
Amler, E. 719–723
Andersen, S.E. 99–106
Angst, C.P. 79–86
Armstrong, A.L. 685–690
Aronson, J.K. 725–731
Arthur, J.R. 107–111
Atucha, N.M. 733–738
- Baker, G. 51–58
Barbara, L. 219–223
Barden, A. 711–718
Basse, E.J. 685–690
Beilin, L.J. 449–458, 711–718
Belch, J.F.F. 17–21
Bell, S.C. 169–175
Benn, J. 575–582
Bernard, C. 29–33
Bernardi, L. 35–43
Bianchetti, M.G. 347–351
Binah, O. 233–239
Blakemore, S.J. 591–599
Bongso, A. 248–249
Boulton, R. 503–507
Bourgin, P. 45–50
Bradford, A. 337–345
Bragado, M.J. 365–369, 771
Bragulat, E. 155–161
Bränström, R. 431–439
Bröijersén, A. 225–231
Brown, K.M. 107–111
Browne, G. 79–86
Brundin, T. 431–439
Bund, S.J. 739–743
Buvry, A. 319–327
- Cacciafesta, A.M. 385–389
Cailmail, S. 29–33
Calverley, P.M.A. 513–518
Calvo, J.J. 365–369, 771
Campbell, B.J. 359–364
Canali, C. 275–281
Carter, J. 513–518
- Cartouzou, G. 209–212
Carver, J.G. 725–731
Caso, G. 99–106
Cassell, T.B. 509–512
Castleden, C.M. 467–474
Cattell, V. 375–384
Celli, V. 385–389
Cester, N. 719–723
Chadwick, I.G. 617–620
Chan, S.H. 256–258
Chan, S.Y. 250–252
Charles, C.J. 283–291
Chin-Dusting, J. 23–28
Christensen, N.J. 621–626
Chua, T.P. 391–398
Cipollina, M.R. 703–710
Claassen, J.A.H.R. 483–488
Clague, J.E. 513–518
Clark, M.L. 425–430
Coats, A.J.S. 391–398
Coca, A. 155–161
Colombani, V. 209–212
Colombo, R. 391–398
Compston, J.E. 307–312
Connell, J.M.C. 65–71
Cook, H.T. 375–384
Coupland, C.A.C. 685–690
Cowley, A.J. 415–423
Crawley, J. 51–58
Crijns, F.R.L. 131–139
Critchley, J.A.J.H. 35–43
Croft, K.D. 449–458, 711–718
Curran, A.K. 337–345
- D'Almeida, M. 29–33
Davies, P.S.W. 763–769
Day, J.M.E. 763–769
de Silva, H.A. 725–731
De Chazal, R. 169–175
De La Sierra, A. 155–161
De Leeuw, P.W. 163–168
De Propriis, A.M. 385–389
De Rooij, M.J.M. 483–488
Del Mar Lluch, M. 155–161
Dessauer, C.W. 527–537
Di Bernardo, M.G. 385–389
Di Virgilio, F. 703–710
Dickinson, C.J. 539–550
Dimitriadou, V. 319–327
Ding, X.-J. 93–98
Dowling, R.H. 509–512
- Drummond, P.D. 73–77
Dudley, F. 23–28
Duner, E. 703–710
Duthie, G.G. 107–111
Dutto, F. 313–318
- Earnest, C.P. 113–118
El-Gamal, N. 627–631
Elia, M. 241–245, 665–677
Elliott, H.L. 65–71
Elliott, R.A. 467–474
Ellory, J.C. 353–358
Engelman, J.L. 509–512
Escourrou, P. 45–50
Espiner, E.A. 283–291
Essén, P. 99–106
Eto, T. 293–298
- Fagbemi, O.S. 745–754
Farak, M.M. 187–191
Farmer, R.D.T. 87–92
Farzaneh, F. 213–218
Feigel, P. 45–50
Felzen, B. 233–239
Feng, Y.-H. 459–466
Finch, P.M. 73–77
Finnie, I.A. 359–364
Flanagan, G.J. 353–358
Forster, C.D. 425–430
Fortepiani, L.A. 733–738
Fowler, B. 79–86
Frank, S.M. 627–631
Frayn, K.N. 425–430, 679–683
Freestone, S. 177–185
Frick, G. 79–86
Frossard, N. 319–327
Frostell, C. 225–231
- Gafter, U. 519–523
Garbarg, M. 319–327
García, L.J. 365–369, 771
García-Estañ, J. 733–738
Garlick, P.J. 99–106
Gaskin, G. 329–335
Gerolami, A. 209–212
Ghosh, S. 213–218
Gibson, A. 633–638
Gilman, A.G. 527–537
Giner, V. 155–161
Giordano, A. 391–398
Glennville, B. 51–58
Goldman, J.M. 329–335

- Goldstein, D. 233–239
 González, A. 365–369, 771
 Goodlad, R.A. 503–507
 Granger, J.P. 497–502
 Green, C.J. 51–58
 Grey, C. 307–312
 Griffin, G.E. 241–245
 Grimble, R.F. 121–130
 Gusmaroli, R. 219–223
 Gustafsson, F. 621–626
- Haefeli, W.E. 79–86
 Hafen, G. 347–351
 Hansen, J.M. 489–496
 Harrington, D. 391–398
 Hart, G. 459–466
 Heagerty, A.M. 739–743
 Heude, E. 45–50
 Hider, R. 633–638
 Higgins, K.S. 617–620
 Hillis, G.S. 639–650
 Hjemdahl, P. 225–231
 Hodgson, H.J. 329–335
 Holton, J. 219–223
 Hong, C.Y. 601–606
 Hoskins, P.R. 17–21
 Houben, A.J.H.M. 163–168
 Huang, Y.-T. 601–606
 Huang, Y.W. 93–98
 Hughes, J.M.B. 329–335
 Humphreys, S.M. 425–430, 679–683
 Hundal, H.S. 591–599
 Hutton, I. 739–743
- Idone, G. 385–389
 Imholz, B.P.M. 193–200
 Ishikawa, T. 755–761
 Ishimitsu, T. 293–298
- Jackson, A.A. 607–615
 Jackson, P.R. 399–413, 617–620, 773–774
 James, M.A. 59–64
 Janssen, M.C.H. 483–488
 Jebb, S.A. 241–245
 Jellema, W.T. 193–200
 Jennings, G. 23–28, 241–245
 Ji, M.R. 93–98
 Johnston, N.R. 177–185
 Jones, D.E.J. 551–558
 Jones, P.H. 141–146
- Kakkar, R. 441–448
 Kalechman, Y. 519–523
 Kalra, J. 441–448
 Kamen, P.W. 201–208
 Kang, J.Y. 252–254
- Kangawa, K. 293–298
 Karet, F.E. 267–273
 Kay, R.L.C. 35–43
 Kearney, M.T. 415–423
 Kemp, G.J. 691–702
 Kersten, A.H. 475–481
 Kime, R. 633–638
 Kirchner, K.A. 497–502
 Kirstetter, P. 29–33
 Kitamura, K. 293–298
 Knudsen, J.H. 621–626
 Konje, J.C. 169–175
 Korten, E.C.C.M. 163–168
 Kosoglou, T. 283–291
 Kraskiewicz, M. 617–620
 Krum, H. 201–208
 Kurashina, T. 497–502
- Lahiri, A. 51–58
 Lainchbury, J.G. 3–16, 525
 Langley-Evans, S.C. 607–615
 Laux-End, R. 347–351
 Lawson, K. 651–663
 Lebrec, D. 29–33
 Lee, K.O. 254–256
 Lee, M.R. 177–185
 Leijssen, D.P.C. 665–677
 Lérique, B. 209–212
 Lewins, P. 87–92
 Lewis, L. 3–16, 525
 Leyssac, P.P. 489–496
 Li, X.C. 147–154
 Li Kam Wa, T.C. 177–185
 Ligtenberg, J.J.M. 583–589
 Lin, H.-C. 601–606
 Links, T.P. 583–589
 Liu, C. 93–98
 Liu, T.-B. 601–606
 Lo, T.W.C. 575–582
 Lockhart, A. 319–327
 Loehrer, F.M.T. 79–86
 López, M.A. 365–369, 771
 Lotan, R. 233–239
 Lucarelli, G. 719–723
 Lutterman, J.A. 559–565
- Macallan, D.C. 241–245
 Macdonald, I.A. 415–423, 425–430
 MacLeod, A.M. 639–650
 Macpherson, M.B. 685–690
 Mantha, S.V. 441–448
 Marangella, M. 313–318
 Marigliano, V. 385–389
 Marteau, C. 209–212
 Martínez, C. 733–738
 Matsuo, H. 293–298
- Matsuoka, H. 293–298
 May, H. 307–312
 Mazzanti, L. 719–723
 Mazzuero, G. 391–398
 McGuigan, J.A.S. 347–351
 McKie, A.T. 213–218
 McLellan, A.C. 575–582
 McNally, P.G. 59–64
 McNurlan, M.A. 99–106
 Menegatti, M. 219–223
 Menys, V.C. 87–92
 Michael, C.A. 711–718
 Miglioli, M. 219–223
 Mikhail, M. 187–191
 Millar, J.A. 567–573
 Milton, J.D. 359–364
 Minami, J.-I. 293–298
 Mione, V. 275–281
 Miranda, F. 219–223
 Mitchell, T.L. 113–118
 Moreau, R. 29–33
 Mormino, P. 275–281
 Morrice, P.C. 107–111
 Morris, A.D. 65–71
 Morris, R.J. 679–683
 Morton, J.J. 169–175
 Murphy, G.M. 509–512
 Murphy, S. 307–312
- Netten, P.M. 559–565
 Newlands, G.F.J. 319–327
 Ng, S.C. 254–256
 Nicholls, M.G. 3–16, 283–291, 525
 Nicolosi, G. 275–281
 Nishikimi, T. 293–298
 Nishino, T. 755–761
 Noble, M.I.M. 87–92
 Nocco, M.L. 385–389
 Norman, R.I. 467–474
 Northover, B.J. 745–754
 Nosadini, R. 703–710
- O'Brien, S.F. 567–573
 O'Halloran, K.D. 337–345
 O'Kelly, J. 353–358
 Osborne, J. 685–690
 Oh, V.M.S. 247, 261–264
 Oldroyd, B. 763–769
 Olsen, N.V. 489–496
 Ortíz, M.C. 733–738
- Palatini, P. 275–281
 Panerai, R. 59–64
 Parker, S.G. 467–474
 Patel, A.R. 497–502
 Paton, N.I.J. 241–245
 Payne, J.N. 399–413, 773–774

- Pearson, M.G. 513–518
 Peeters, L.L.H. 163–168
 Peheim, E. 347–351
 Pereira, S.P. 509–512
 Pessina, A.C. 275–281
 Peters, A.M. 329–335
 Peters, T.J. 213–218
 Petrarulo, M. 313–318
 Petrie, J.R. 65–71
 Pickin, D.M. 399–413, 773–774
 Piepoli, M. 391–398
 Playford, R.J. 503–507
 Plusa, S.M. 371–374
 Poaty, V. 319–327
 Ponikowski, P. 391–398
 Posner, B.A. 527–537
 Potter, J.F. 59–64
 Powers, H. 633–638
 Prasad, K. 441–448
 Primrose, J.N. 371–374
 Proudfoot, J.M. 449–458
 Puddey, I.B. 449–458
 Pusey, C.D. 329–335

 Qureshi, I.A. 93–98

 Rabini, R.A. 719–723
 Radda, G.K. 691–702
 Rademaker, M.T. 283–291
 Rae, C. 353–358
 Raja, S.N. 627–631
 Ramsay, L.E. 399–413, 617–620,
 773–774
 Ravel, U. 51–58
 Recchi, D. 385–389
 Reitsma, W.D. 583–589
 Ren, E.C. 256–258
 Rennie, M.J. 591–599
 Rhodes, J.M. 359–364
 Ricci, C. 219–223
 Richards, A.M. 3–16, 283–291,
 525
 Rickhuss, P.K. 591–599
 Ritchie, J. 711–718
 Rooyackers, O.E. 475–481
 Rouleau, A. 319–327
 Rovera, L. 313–318
 Ryan, J. 23–28

 Sadek, S.K. 359–364
 Samra, J.S. 425–430, 679–683
 Samson, R.R. 177–185
 San Román, J.I. 365–369, 771
 Sanderson, A.L. 691–702
 Sanderson, J.E. 35–43
 Savill, J. 329–335

 Schibler, A. 347–351
 Schwartz, J.-C. 319–327
 Scuteri, A. 385–389
 Selldén, E. 431–439
 Shan, Y.-F. 93–98
 Shehata, R. 187–191
 Sherman, R.C. 607–615
 Shirley, D.G. 299–305
 Shurey, C. 51–58
 Silvester, W. 567–573
 Silviani, V. 209–212
 Simpson, E.J. 425–430
 Simpson, R.J. 213–218
 Skipworth, S. 73–77
 Sladen, G.E. 509–512
 Sluiter, W.J. 583–589
 Smit, A.J. 583–589
 Smith, C.C.T. 87–92
 Smith, M.A. 763–769
 Sönksen, P.H. 575–582
 Soupison, T. 29–33
 Sredni, B. 519–523
 Staffolani, R. 719–723
 Stolte, J. 131–139
 Stonebridge, P.A. 17–21
 Stritoni, P. 275–281
 Struijker-Boudier,
 H.A.J. 131–139
 Stubbs, T.A. 415–423
 Sugimori, K. 755–761
 Summers, L.K.M. 679–683
 Swales, J.D. 59–64

 Tan, C.-C. 258–260
 Tavakoli, R. 319–327
 Tay, A. 264–266
 Taylor, B.A. 359–364
 Taylor, D.J. 169–175
 Taylor, E.A. 261–264
 Tedgui, A. 29–33
 Thien, Th. 483–488, 559–565
 Thompson, C.H. 691–702
 Thorell, A. 99–106
 Thornalley, P.J. 575–582
 Thorniley, M.S. 51–58
 Thurston, H. 59–64
 Tjäder, I. 99–106
 Toft, J. 621–626
 Tomlinson, B. 35–43
 Tonkin, A.M. 201–208
 Trevisan, M. 703–710
 Trevisan, R. 703–710
 Truttmann, A.C. 347–351
 Tsai, J.-F. 601–606
 Turney, J.H. 763–769

 Tweddel, A. 739–743

 Ueda, S. 65–71
 Ul Haq, I. 399–413, 773–774
 Unwin, R.J. 299–305
 Urbano-Márquez, A. 155–161
 Ussov, W.Yu 329–335

 Vaira, D. 219–223
 Van Asten, W.N.J.C. 483–488
 Van Beek, E. 163–168
 Van der Kolk, L.E. 583–589
 Van Es, P.N. 163–168
 Van Essen, H. 131–139
 Van Goudoever, J. 193–200
 Van Haften, T.W. 583–589
 Van Lieshout, J.J. 193–200
 Visentin, P. 275–281
 Vitale, C. 313–318
 Volterrani, M. 391–398

 Wagenmakers, A.J.M. 475–481
 Wallace, W.A. 685–690
 Wallén, N.H. 225–231
 Walter, S.J. 299–305
 Walters, B.N. 711–718
 Watt, P.W. 591–599
 Watts, G.F. 567–573
 Webster, N. 371–374
 Welham, S.J.M. 607–615
 Wernerman, J. 99–106
 Wesseling, K.H. 193–200
 Weston, P.J. 59–64
 Whitaker, R.P. 467–474
 Widdop, R.E. 147–154
 Willekes, C. 163–168
 Winearls, C.G. 353–358
 Wollersheim, H. 483–488,
 559–565
 Woo, K.S. 35–43
 Woodrow, G. 763–769
 Wu, P.K. 627–631

 Xie, Y. 93–98

 Yang, M.C.-M. 601–606
 Yang, S. 29–33
 Yeo, W.W. 399–413, 617–620,
 773–774
 Yeung, D.T.K. 35–43
 Yeung, L.Y.C. 35–43
 Yong, W. 633–638
 Youdim, M. 233–239
 Young, R. 307–312
 Yu, L.-G. 359–364

 Zolese, G. 719–723

Volume 91

SUBJECT INDEX

First and last page numbers of papers to which entries refer are given. Page numbers marked with an asterisk refer to Reviews.

- Accidental falls
oestrogen replacement therapy 685–690
- Acetylcholine
endothelium, Syndrome X 739–743
nitric oxide, liver cirrhosis 733–738
- Action potential
cardiac muscle, nutritional iron deficiency 233–239
- Activation energy
Na⁺, K⁺-ATPase, gestational hypertension 719–723
- S-Adenosylhomocysteine
metabolism 79–86
- S-Adenosylmethionine
metabolism 79–86
- Adenylate cyclase
G-proteins, signal transduction 527–537*
- Adipose tissue
microdialysis, catecholamines 425–430
- Adipose tissue blood flow
body mass index 679–683
- Adrenaline
lymphocytes, cyclic AMP 612–626
- α -Adrenergic receptors
skin, reflex sympathetic dystrophy 73–77
- Adrenergic β_2 -receptors
lymphocytes, noradrenaline 621–626
- α -Adrenoceptor antagonist
thermoregulation 627–631
- Adrenomedullin
G-protein-linked receptors, cyclic AMP 3–16*, 525
salt, essential hypertension 293–298
- Ageing
lymphocytes, cyclic AMP 621–626
- Alcohol
pancreatitis-associated protein messenger RNA 213–218
- Alcoholic cirrhosis
nitric oxide 23–28
- Aliphatic amines
renal failure, choline transport 353–358
- Alkalosis
hyperventilation, magnesium 347–351
- Almitrine
ventilation, muscle activity 337–345
- Ambulatory blood pressure
left ventricular function, hypertension 275–281
- Ambulatory monitoring
blood pressure, sleep 45–50
- Amino acids
inflammation, cytokines 121–130*
metabolism, vascular disease 79–86
renal transplant recipients, cyclosporin A 489–496
thermogenesis, anaesthesia 431–439
- Aminoglycosides
nephrotoxicity, non-steroidal anti-inflammatory drugs 187–191
- Amylase release
pancreatitis 365–369, 771
- Anaesthesia
amino acids, thermogenesis 431–439
- Angina
cholesterol, lipids 399–413, 773–774
- Angiotensin II
microalbuminuria, non-insulin-dependent diabetes 703–710
- Angiotensin type 1 receptor antagonists
renal vasodilatation, spontaneously hypertensive rats 147–154
- Angiotensin-converting enzyme
genetic polymorphism, bradykinin 617–620
- Antioxidant enzyme
vitamin E, smoking 107–111
- Antioxidants
inflammation, cytokines 121–130*
- Antisense oligodeoxynucleotides
multidrug resistance 93–98
- Aorta
nitric oxide, liver cirrhosis 733–738
- Arachidonic acid
phospholipids, Crohn's disease 509–512
- Arterialization
insulin sensitivity, forearm blood flow 65–71
- Artery
morphology, syndrome X 739–743
- ATP synthesis

- exercise, obesity 691–702
- ATP-sensitive potassium channels
 - potassium channel openers 651–663*
- Atrial natriuretic peptide
 - neutral endopeptidase, ventricular
 - pacing 283–291
 - salt, essential hypertension 293–298
 - potassium channel openers 651–663*
- Autoantigen
 - T-lymphocytes, biliary cirrhosis 551–558
- Autoimmunity
 - T-lymphocytes, biliary cirrhosis 551–558
- Autonomic function
 - baroreflex sensitivity, insulin-dependent diabetes mellitus 59–64
- Autonomic nervous system
 - heart failure, heart rate variability 391–398
 - heart failure, spectral power 35–43
 - Poincaré plot, heart rate variability 201–208
- Autoregulation
 - Na⁺, K⁺-ATPase, ouabain 497–502
- Balance
 - oestrogen replacement therapy 685–690
- Baroreflex sensitivity
 - autonomic function, insulin-dependent diabetes mellitus 59–64
- Bicarbonate-urea method
 - energy expenditure, human immunodeficiency virus infection 241–245
- Biliary cirrhosis
 - autoimmunity, T-lymphocytes 551–558
- Blastocyst transfer
 - human embryos 248–249
- Bleeding time
 - inhaled nitric oxide 225–231
- Blood flow
 - vascular disease, ultrasound 17–21
- Blood pressure
 - ambulatory monitoring, sleep 45–50
 - stroke volume, syncope 193–200
- Blood temperature
 - amino acids, anaesthesia 431–439
- Blood transfusion
 - T-helper 2 cytokines, transforming growth factor 519–523
- Body composition
 - chronic kidney failure 763–769
- Body mass index
 - adipose tissue blood flow 679–683
- Bone mineral density
 - postmenopausal women 307–312
- Bone resorption
 - calcium nephrolithiasis, mineral water 313–318
- Bradykinin
 - angiotensin-converting enzyme, genetic polymorphism 617–620
 - endothelium, Syndrome X 739–743
- Brain
 - oxidative metabolism, hypertension 539–550
- Brain natriuretic peptide
 - neutral endopeptidase, ventricular
 - pacing 283–291
- Breath-holding time
 - control of breathing, dyspnoea 755–761
- Bronchial hyper-responsiveness
 - lung transplantation, mast cells 319–327
- Bumetanide
 - Na⁺/K⁺/2Cl⁻ co-transport 725–731
- Caerulein
 - pancreatitis, intracellular calcium 365–369, 771
- Caffeic acid
 - lipoprotein oxidation, wine 449–458
- Calcium
 - alkalosis, hyperventilation 347–351
- Calcium antagonist
 - oxidants 459–466
 - urinary bladder 467–474
- Calcium nephrolithiasis
 - mineral water 313–318
- Calcium oxalate
 - urine state of saturation, calcium nephrolithiasis 313–318
- Calcium phosphate
 - urine state of saturation, calcium nephrolithiasis 313–318
- Calf muscle pump function
 - validation, chronic venous insufficiency 483–488
- Cancer
 - eicosanoid production 264–266
 - Helicobacter pylori*, serology 219–223
- Capillaroscopy
 - microcirculation 131–139*
- Capsaicin
 - chilli, stomach 252–254
- Carbon dioxide
 - inspiratory effort sensation, sustained loading 513–518
 - recovery 665–677
- Cardiac muscle
 - nutritional iron deficiency 233–239
- Cardiac oxygenation
 - ischaemia, spectrophotometry 51–58
- Catalase
 - diabetes 441–448
- Catecholamines
 - adipose tissue, microdialysis 425–430
- Cell adhesion
 - epidermal stem cells, integrins 141–146*

- Cell adhesion molecules
 - integrins 639–650*
- Cell differentiation
 - epidermal stem cells 141–146*
- Cell division
 - epidermal stem cells 141–146*
- Cell proliferation
 - epidermal growth factor, gastrointestinal tract 503–507
- Cerebral blood supply
 - hypertension 539–550
- Cerebrovascular disease
 - hypertension 539–550
- Cervical carcinoma
 - DNA testing, papillomavirus 250–252
- Chemiluminescence
 - oxidants, calcium antagonist 459–466
- Chemoreceptors
 - heart failure, heart rate variability 391–398
- Chilli
 - capsaicin, stomach 252–254
- Cholecystokinin 8
 - intracellular calcium, pancreatitis 365–369, 771
- Cholesterol
 - coronary heart disease, lipids 399–413, 773–774
- Cholesterol metabolism
 - creatine supplementation 113–118
- Choline transport
 - renal failure, haemodialysis 353–358
- Chronic kidney failure
 - body composition 763–769
- Chronic venous insufficiency
 - calf muscle pump function, validation 483–488
- Cirrhosis
 - tumour necrosis factor- α , pentoxifylline 29–33
- Clinical research
 - progress in Singapore 247–266
- Colonic mucin
 - corticosteroids, nicotine 359–364
- Contractile response
 - portal hypertension, octreotide 601–606
- Contractility
 - cardiac muscle, nutritional iron deficiency 233–239
- Control of breathing
 - breath-holding time, dyspnoea 755–761
- Coronary heart disease
 - cholesterol, lipids 399–413, 773–774
- Coronary risk
 - lipids 399–413, 773–774
- Corticosteroids
 - mucin, colon 359–364
- Creatine supplementation
 - lipid metabolism 113–118
- Crohn's disease
 - fatty acids, phospholipids 509–512
- Cromakalim
 - therapeutic targets 651–663*
- CV-11974
 - renal vasodilatation, spontaneously hypertensive rats 147–154
- Cyclic AMP
 - G-protein-linked receptors, adrenomedullin 3–16*, 525
 - G-proteins, signal transduction 527–537*
 - lymphocytes, noradrenaline 621–626
- Cyclic GMP
 - inhaled nitric oxide 225–231
 - neutral endopeptidase, ventricular pacing 283–291
- Cyclosporin A
 - renal transplant recipients 489–496
- Cytochrome *aa₃*
 - ischaemia, spectrophotometry 51–58
- Cytochrome *c* oxidase
 - muscle wasting, zymosan 475–481
- Cytokine
 - pentoxifylline, cirrhosis 29–33
- Cytokines
 - nutrients, inflammation 121–130*
- Densitometry
 - chronic kidney failure 763–769
- Dermis
 - α -adrenergic receptors, reflex sympathetic dystrophy 73–77
- Diabetes
 - endothelium, dyslipidaemia 567–573
 - microcirculation 131–139*
 - oxidative stress 441–448
 - oxidative stress, glyoxylase 575–582
- Diabetes mellitus
 - baroreflex sensitivity, autonomic function 59–64
- Diabetic foot
 - skin microcirculation, neuropathy 559–565
- Diaphragm
 - almitrine, electromyography 337–345
- Diclofenac sodium
 - nephrotoxicity, gentamicin 187–191
- DNA testing
 - papillomavirus, cervical carcinoma 250–252
- Dopamine
 - 5-hydroxytryptamine, renal sodium excretion 177–185
 - renal transplant recipients, cyclosporin A 489–496
- Dyslipidaemia
 - diabetes, endothelium 567–573
- Dyspnoea

- control of breathing, breath-holding time 755–761
- Echocardiography
 - left ventricular function, hypertension 275–281
- EEG arousal
 - blood pressure, sleep 45–50
- Eicosanoid production
 - hypertension, cancer 264–266
- Electromyography
 - muscle activity, almitrine 337–345
- Embryos
 - blastocyst transfer, stem cell production 248–249
- Endothelin
 - salt, essential hypertension 293–298
- Endothelin peptides
 - human kidney 267–273*
- Endothelin receptors
 - human kidney 267–273*
- Endothelium
 - diabetes, dyslipidaemia 567–573
 - phenylephrine, liver cirrhosis 733–738
 - Syndrome X 739–743
- Energy expenditure
 - bicarbonate-urea method, human immunodeficiency virus infection 241–245
- Epidermal growth factor
 - cell proliferation, gastrointestinal tract 503–507
- Epidermal stem cells
 - cell adhesion, integrins 141–146*
- Epidermis
 - α -adrenergic receptors, reflex sympathetic dystrophy 73–77
- Epilepsy
 - genetic analysis 264–266
- Erythropoietin dysregulation
 - renal failure 258–260
- Essential hypertension
 - salt, adrenomedullin 293–298
- Exercise
 - ATP synthesis, obesity 691–702
- EXP 3174
 - renal vasodilatation, spontaneously hypertensive rats 147–154
- Familial hypokalaemic periodic paralysis
 - sodium pump 261–264
- Fatiguability
 - cytochrome *c* oxidase, zymosan 475–481
- Fatigue
 - inspiratory effort sensation, CO₂ responsiveness 513–518
- Fats
 - inflammation, cytokines 121–130*
- Fatty acids
 - phospholipids, Crohn's disease 509–512
- Fetal programming
 - maternal nutrition, hypertension 607–615
- Fetuses
 - gestational age, kidney 169–175
- Fibroblasts
 - intracellular pH, free cytosolic calcium 703–710
- Flooding dose
 - muscle wasting, zymosan 475–481
- Fluidity
 - Na⁺, K⁺-ATPase, gestational hypertension 719–723
- Fluoxetine
 - 5-hydroxytryptamine, platelet aggregation 87–92
- Forearm blood flow
 - arterialization 65–71
 - menstrual cycle 163–168
- Free cytosolic calcium
 - microalbuminuria, non-insulin-dependent diabetes 703–710
- Frusemide
 - sodium depletion 299–305
- Gallbladder
 - sodium/hydrogen exchanger, sodium absorption 209–212
- Gastrointestinal tract
 - cell proliferation, epidermal growth factor 503–507
- Gene expression
 - pancreatitis-associated protein, mouse intestine 213–218
- Genetic analysis
 - research in Singapore 264–266
- Genetic polymorphism
 - angiotensin-converting enzyme, bradykinin 617–620
- Geniohyoid
 - almitrine, electromyography 337–345
- Gentamicin
 - nephrotoxicity, non-steroidal anti-inflammatory drugs 187–191
- Gestational age
 - renin, kidney 169–175
- Gestational hypertension
 - Na⁺, K⁺-ATPase 719–723
- Glomerular filtration rate
 - renal transplant recipients, cyclosporin A 489–496
- Glomerulonephritis
 - IgA nephropathy 258–260
- Glucocorticoids
 - fetal programming, hypertension 607–615
- Glucose transport
 - sarcolemma, insulin 591–599

- Gludopa
 renal metabolism 177–185
 γ -L-Glutamyl-5-hydroxy-L-tryptophan
 renal metabolism 177–185
 Glutathione
 antioxidants, cytokines 121–130*
 Glutathione peroxidase
 diabetes 441–448
 Glycogenolysis
 exercise, obesity 691–702
 Glyoxal
 diabetes, oxidative stress 575–582
 Glyoxylase
 diabetes, oxidative stress 575–582
 G-protein-linked receptors
 adrenomedullin, cyclic AMP 3–16*, 525
 G-proteins
 signal transduction, adenylate cyclase 527–537*
 Granulocyte activation
 inflammatory disease 329–335
 Granulocyte pool
 ^{111}In - $^{99\text{m}}\text{Tc}$ -labelled granulocytes, inflammatory
 disease 329–335
 Grape juice
 phenolic compounds, lipoprotein
 oxidation 449–458
 Growth hormone
 male infertility 254–256
 Haemodialysis
 blood transfusion 519–523
 renal failure, choline transport 353–358
 Haemodynamics
 ischaemia, spectrophotometry 51–58
 meal ingestion, insulin 415–423
 neutral endopeptidase, ventricular
 pacing 283–291
 pentoxifylline, cirrhosis 29–33
 Heart failure
 adrenomedullin 3–16*, 525
 autonomic nervous system, spectral power 35–43
 heart rate variability, autonomic nervous
 system 391–398
 Heart rate
 blood pressure, sleep 45–50
 Heart rate variability
 autonomic nervous system, spectral power 35–43
 heart failure, autonomic nervous
 system 391–398
 Poincaré plot, parasympathetic nervous
 system 201–208
Helicobacter pylori
 serology, cancer 219–223
 High-performance liquid chromatography
 non-transferrin-bound iron, preterm
 babies 633–638
 Hip
 bone-mineral density, postmenopausal
 women 307–312
 Homocysteine
 metabolism 79–86
 Hormone replacement therapy
 bone mineral density, postmenopausal
 women 307–312
 Human immunodeficiency virus infection
 energy expenditure, bicarbonate-urea
 method 241–245
 Human leucocyte antigens
 nasopharyngeal carcinoma 256–258
 5-Hydroxytryptamine
 dopamine, renal sodium excretion 177–185
 platelet aggregation, fluoxetine 87–92
 Hyperglycaemia
 insulin release, muscle strength 583–589
 Hyperinsulinaemic euglycaemic clamp
 insulin sensitivity, arterialization 65–71
 Hypertension
 adrenomedullin 3–16*, 525
 contractile response, octreotide 601–606
 eicosanoid production 264–266
 fetal programming, maternal nutrition 607–615
 left ventricular function,
 echocardiography 275–281
 microcirculation 131–139*
 Na^+ , K^+ -ATPase, ouabain 497–502
 oxidative metabolism, brain 539–550
 renin, gestational age 169–175
 salt, adrenomedullin 293–298
 salt sensitivity 155–161
 Hyperventilation
 alkalosis, magnesium 347–351
 Hypokalaemic periodic paralysis
 insulin release 583–589
 sodium pump 261–264
 Hypometabolism
 amino acids, anaesthesia 431–439
 Hypotension
 stroke volume, syncope 193–200
 Hypothermia
 α -adrenoceptor antagonist 627–631
 amino acids, anaesthesia 431–439
 Hypothermic preservation
 rat heart, protein kinase C inhibitors 745–754
 Hypoxia
 pancreatitis-associated protein
 messenger RNA 213–218
 Ibuprofen
 nephrotoxicity, gentamicin 187–191
 IgA nephropathy

- primary glomerulonephritis 258–260
- Immune complex disease
 - inflammation mediators, nitric oxide 375–384*
- Immunity
 - nitric oxide 375–384*
- Immunostaining
 - mast cells, lung transplantation 319–327
- ¹¹¹In–^{99m}Tc-labelled granulocytes
 - lung granulocyte pool, inflammatory disease 329–335
- Infertility
 - growth hormone 254–256
- Inflammation
 - nutrients, cytokines 121–130*
- Inflammation mediators
 - nitric oxide, immune complex disease 375–384*
- Inflammatory disease
 - granulocyte activation, lung granulocyte pool 329–335
- Inhaled nitric oxide
 - platelet function 225–231
- Innervation
 - lung transplantation 319–327
- Inspiratory effort sensation
 - CO₂ responsiveness, sustained loading 513–518
- Insulin
 - adipose tissue blood flow 679–683
 - glucose transport, sarcolemma 591–599
 - microalbuminuria, non-insulin-dependent diabetes 703–710
 - regional haemodynamics, meal ingestion 415–423
- Insulin release
 - hypokalaemic periodic paralysis 583–589
- Insulin sensitivity
 - arterialization 65–71
- Insulin-dependent diabetes mellitus
 - baroreflex sensitivity, autonomic function 59–64
- Integrins
 - cell adhesion, epidermal stem cells 141–146*
 - cell adhesion molecules 639–650*
- Interleukin
 - blood transfusion 519–523
 - nutrients, inflammation 121–130*
- Intracellular calcium
 - pancreatitis 365–369, 771
- Intracellular pH
 - microalbuminuria, non-insulin-dependent diabetes 703–710
- Intravenous nutrition
 - epidermal growth factor 503–507
- Intravital microscopy
 - microcirculation 131–139*
- Inulin clearance
 - menstrual cycle 163–168
- Iron deficiency
 - pancreatitis-associated protein messenger RNA 213–218
- Iron overload
 - pancreatitis-associated protein messenger RNA 213–218
- Ischaemia
 - cardiac oxygenation, spectrophotometry 51–58
 - oxidants, calcium antagonist 459–466
- Iso-electric focusing
 - serology, cancer 219–223
- Iso-prostane
 - lipid peroxidation, pregnancy 711–718
- Keratinocytes
 - epidermal stem cells 141–146*
- Kidney
 - endothelins 267–273*
 - fetal programming, hypertension 607–615
 - renin, gestational age 169–175
- Labelled carbon dioxide
 - recovery 665–77
- Left ventricular function
 - echocardiography, hypertension 275–281
- Lipid
 - neutrophils, sepsis 371–374
- Lipid metabolism
 - creatinine supplementation 113–118
- Lipid peroxidation
 - diabetes 441–448
 - pre-eclampsia, pregnancy 711–718
 - vitamin E, smoking 107–111
- Lipids
 - coronary heart disease, cholesterol 399–413, 773–774
- Lipoprotein oxidation
 - phenolic compounds, wine 449–458
- Lithium clearance
 - renal transplant recipients, cyclosporin A 489–496
- Liver
 - autoimmunity, T-lymphocytes 551–558
- Liver cirrhosis
 - phenylephrine, nitric oxide 733–738
- Loop of Henle
 - sodium depletion, frusemide 299–305
- Loss of label
 - carbon dioxide 665–677
- Lung granulocyte pool
 - ¹¹¹In–^{99m}Tc-labelled granulocytes, inflammatory disease 329–335
- Lung transplantation
 - mast cells, bronchial hyper-responsiveness 319–327
- Lymphocytes
 - cyclic AMP, noradrenaline 621–626
 - protein synthesis, stable isotope 99–106

- Magnesium**
 alkalosis, hyperventilation 347–351
- Magnetic resonance spectroscopy**
 ATP synthesis 691–702
- Male infertility**
 growth hormone 254–256
- Mast cells**
 lung transplantation, bronchial
 hyper-responsiveness 319–327
- Maternal nutrition**
 fetal programming, hypertension 607–615
- Meal ingestion**
 regional haemodynamics, insulin 415–423
- Mean arterial pressure**
 metabolic risk factors, sex 385–389
- Membrane**
 sarcolemma, glucose transport 591–599
- Membrane current**
 cardiac muscle, nutritional iron
 deficiency 233–239
- Menstrual cycle**
 sex hormones, vascular relaxation 163–168
- Mesenteric artery**
 contractile response, octreotide 601–606
- Messenger RNA**
 pancreatitis-associated protein, mouse
 intestine 213–218
- Metabolic risk factors**
 blood pressure, sex 385–389
- Metabolism**
 amino acids, vascular disease 79–86
 thermoregulation, α -adrenoceptor
 antagonist 627–631
- Methodology**
 labelled carbon dioxide, recovery 665–677
- Methylglyoxal**
 diabetes, oxidative stress 575–582
- 5-Methyltetrahydrofolate**
 metabolism 79–86
- Microalbuminuria**
 intracellular pH, free cytosolic calcium 703–710
- Microcirculation**
 cardiovascular disease 131–139*
 diabetic foot, neuropathy 559–565
- Microdialysis**
 adipose tissue, catecholamines 425–430
- Microperfusion**
 loop of Henle, frusemide 299–305
- Micropuncture**
 sodium depletion, frusemide 299–305
- Mineral water**
 calcium nephrolithiasis 313–318
- Mitochondria**
 ischaemia, spectrophotometry 51–58
- Morphology**
 artery, Syndrome X 739–743
- Mouse intestine**
 pancreatitis-associated protein,
 messenger RNA 213–218
- Mucin**
 corticosteroids, nicotine 359–364
- Multidrug resistance**
 antisense oligodeoxynucleotides 93–98
- Muscle**
 oestrogen replacement therapy 685–690
- Muscle metabolism**
 exercise, obesity 691–702
- Muscle strength**
 hypokalaemic periodic paralysis 583–589
- Muscle wasting**
 cytochrome *c* oxidase, zymosan 475–481
- Myocardial infarction**
 cholesterol, lipids 399–413, 773–774
- Na⁺/K⁺/2Cl⁻ co-transport**
 platelets 725–731
- Na⁺, K⁺-ATPase**
 gestational hypertension 719–723
 ouabain, hypertension 497–502
- Nasopharyngeal carcinoma**
 human leucocyte antigens 256–258
- Natriuresis**
 adrenomedullin 3–16*, 525
 neutral endopeptidase, ventricular
 pacing 283–291
- Natriuretic peptides**
 neutral endopeptidase, ventricular
 pacing 283–291
- Natural killer cells**
 cyclic AMP, noradrenaline 621–626
- Nephrotoxicity**
 gentamicin, non-steroidal anti-inflammatory
 drugs 187–191
- Neuropathy**
 diabetic foot, skin microcirculation 559–565
- Neutral endopeptidase**
 natriuretic peptides, ventricular pacing 283–291
- Neutrophils**
 total parenteral nutrition, sepsis 371–374
- Nicotine**
 mucin, colon 359–364
- Nitric oxide**
 alcoholic cirrhosis 23–28
 diabetes, dyslipidaemia 567–573
 immunity 375–384*
 phenylephrine, liver cirrhosis 733–738
 platelet function 225–231
- Nitric oxide synthase**
 immunity 375–384*
- Non-insulin-dependent diabetes**
 intracellular pH, free cytosolic calcium 703–710
- Non-steroidal anti-inflammatory drugs**
 nephrotoxicity, gentamicin 187–191
- Non-transferrin-bound iron**
 high-performance liquid chromatography, preterm
 babies 633–638
- Noradrenaline**
 lymphocytes, cyclic AMP 621–626

- salt sensitivity, hypertension 155–161
- Nutrients
 - inflammation, cytokines 121–130*
- Nutritional iron deficiency
 - cardiac muscle 233–239
- Obesity
 - adipose tissue blood flow 679–683
 - ATP synthesis, exercise 691–702
- Octreotide
 - contractile response, portal hypertension 601–606
- Oestrogen replacement therapy
 - muscle, balance 685–690
- Ouabain
 - Na⁺, K⁺-ATPase, hypertension 497–502
- Oxidants
 - calcium antagonist 459–466
- Oxidation
 - exercise, obesity 691–702
- Oxidative metabolism
 - brain, hypertension 539–550
- Oxidative stress
 - diabetes 441–448
 - diabetes, glyoxylase 575–582
- Oxygen consumption
 - oxidants, calcium antagonist 459–466
- Pancreatic acinar cells
 - intracellular calcium, pancreatitis 365–369, 771
- Pancreatitis
 - intracellular calcium 365–369, 771
- Pancreatitis-associated protein
 - messenger RNA, mouse intestine 213–218
- Papillomavirus
 - DNA testing, cervical carcinoma 250–252
- Para*-aminohippurate clearance
 - menstrual cycle 163–168
- Parasympathetic nervous system
 - Poincaré plot, heart rate variability 201–208
- Parenteral nutrition
 - epidermal growth factor 503–507
- Pentoxifylline
 - tumour necrosis factor- α , cirrhosis 29–33
- Phagocytosis
 - oxidants, calcium antagonist 459–466
- Phenolic compounds
 - lipoprotein oxidation, wine 449–458
- Phentolamine
 - thermoregulation 627–631
- Phenylephrine
 - contractile response, octreotide 601–606
 - nitric oxide, liver cirrhosis 733–738
- Phosphocreatine breakdown
 - exercise, obesity 691–702
- Phospholipids
 - fatty acids, Crohn's disease 509–512
- Physical activity
 - bicarbonate-urea method, human immunodeficiency virus infection 241–245
- Physical fitness
 - lymphocytes, cyclic AMP 621–626
- Pinacidil
 - insulin release, muscle strength 583–589
- Placenta
 - Na⁺, K⁺-ATPase, gestational hypertension 719–723
- Platelet aggregation
 - 5-hydroxytryptamine, fluoxetine 87–92
 - inhaled nitric oxide 225–231
- Platelets
 - Na⁺/K⁺/2Cl⁻ co-transport 725–731
- Plethysmography
 - calf muscle pump function 483–488
 - forearm blood flow, arterialization 65–71
- Poincaré plot
 - parasympathetic nervous system, heart rate variability 201–208
- Polymerase chain reaction
 - renal endothelins 267–273*
- Portal hypertension
 - contractile response, octreotide 601–606
 - pentoxifylline, cirrhosis 29–33
- Post-menopause
 - oestrogen replacement therapy 685–690
- Post-thrombotic syndrome
 - calf muscle pump function, validation 483–488
- Postmenopausal women
 - bone mineral density 307–312
- Posture
 - spectral power 35–43
- Potassium
 - alkalosis, hyperventilation 347–351
- Potassium channel openers
 - therapeutic targets 651–663*
- Pre-eclampsia
 - lipid peroxidation 711–718
- Pregnancy
 - lipid peroxidation 711–718
- Pressure natriuresis
 - Na⁺, K⁺-ATPase, ouabain 497–502
- Preterm babies
 - non-transferrin-bound iron, high-performance liquid chromatography 633–638
- Primary prevention
 - coronary heart disease 399–413, 773–774
- Protease
 - mast cells, lung transplantation 319–327
- Protein kinase C inhibitors
 - rat heart, hypothermic preservation 745–754
- Protein synthesis
 - lymphocytes, stable isotope 99–106
- Pulse pressure
 - metabolic risk factors, sex 385–389
- Rat heart
 - hypothermic preservation, protein kinase C inhibitors 745–754
- Recovery

- labelled carbon dioxide 665–677
- Reflex sympathetic dystrophy
 - α -adrenergic receptors, skin 73–77
- Renal endothelins
 - quantitative polymerase chain reaction analysis 267–273*
- Renal failure
 - choline transport, haemodialysis 353–358
 - erythropoietin dysregulation 258–260
- Renal plasma flow
 - renal transplant recipients, cyclosporin A 489–496
- Renal sodium excretion
 - dopamine, 5-hydroxytryptamine 177–185
- Renal transplant recipients
 - amino acids, dopamine 489–496
- Renal tubule
 - sodium depletion, frusemide 299–305
- Renal vasodilatation
 - angiotensin type 1 receptor antagonists, spontaneously hypertensive rats 147–154
- Renin
 - gestational age, kidney 169–175
- Renin–aldosterone axis
 - salt sensitivity, hypertension 155–161
- Resistance arteries
 - nitric oxide, alcoholic cirrhosis 23–28
- Respiratory frequency
 - spectral power 35–43
- Salt
 - adrenomedullin, essential hypertension 293–298
- Salt sensitivity
 - hypertension 155–161
- Sarcolemma
 - glucose transport, insulin 591–599
- Schizophrenia
 - genetic analysis 264–266
- Secondary prevention
 - coronary heart disease 399–413, 773–774
- Sepsis
 - neutrophils, total parenteral nutrition 371–374
- Serology
 - Helicobacter pylori*, cancer 219–223
- Sex
 - metabolic risk factors, blood pressure 385–389
- Sex hormones
 - menstrual cycle, vascular relaxation 163–168
- Signal transduction
 - G-proteins, adenylate cyclase 527–537*
- Singapore
 - genetic studies 264–266
 - progress in clinical research 247–266
- Skeletal muscle blood flow
 - meal ingestion, insulin 415–423
- Skin
 - α -adrenergic receptors, reflex sympathetic dystrophy 73–77
- Skin fibroblasts
 - intracellular pH, free cytosolic calcium 703–710
- Skin microcirculation
 - diabetic foot, neuropathy 559–565
 - menstrual cycle 163–168
- Sleep
 - blood pressure, ambulatory monitoring 45–50
- Smoking
 - antioxidant enzyme, vitamin E 107–111
 - lymphocytes, cyclic AMP 621–626
- Smooth muscle
 - nitric oxide, alcoholic cirrhosis 23–28
- Sodium absorption
 - gallbladder, sodium/hydrogen exchanger 209–212
- Sodium clearance
 - renal transplant recipients, cyclosporin A 489–496
- Sodium depletion
 - frusemide 299–305
- Sodium/hydrogen exchanger
 - gallbladder, sodium absorption 209–212
- Sodium pump
 - hypokalaemic periodic muscle paralysis 261–264
- Spectral power
 - autonomic nervous system, heart failure 35–43
- Spectrophotometry
 - cardiac oxygenation, ischaemia 51–58
- Spermatogenesis
 - growth factors 254–256
- Spine
 - bone mineral density, postmenopausal women 307–312
- Spiral laminar flow
 - vascular disease, ultrasound 17–21
- Splanchnic oxygen uptake
 - amino acids, anaesthesia 431–439
- Spontaneously hypertensive rats
 - oxidative metabolism, brain 539–550
 - renal vasodilatation, angiotensin type 1 receptor antagonists 147–154
- Stable isotope
 - lymphocytes, protein synthesis 99–106
- Stem cell production
 - human embryos 248–249
- Stomach
 - chilli, capsaicin 252–254
- Stroke
 - cholesterol, lipids 399–413, 773–774
- Stroke volume
 - blood pressure, syncope 193–200
- Subcellular fractionation
 - muscle wasting, zymosan 475–481
- Sudden death
 - baroreflex sensitivity, insulin-dependent diabetes mellitus 59–64
- Superoxide dismutase
 - diabetes 441–448
- Surgery

- lymphocytes, protein synthesis 99–106
- Sustained loading
 - inspiratory effort sensation, CO₂ responsiveness 513–518
- Sympathetic nervous system
 - blood pressure, sleep 45–50
- Syncope
 - blood pressure, stroke volume 193–200
- Syndrome X
 - artery, morphology 739–743
- T-cell receptor genes
 - nasopharyngeal carcinoma 256–258
- T-helper 2 cytokines
 - blood transfusion 519–523
- T-lymphocytes
 - autoimmunity, biliary cirrhosis 551–558
- Therapeutic targets
 - potassium channel openers 651–663*
- Thermogenesis
 - amino acids, anaesthesia 431–439
- Thermoregulation
 - α -adrenoceptor antagonist 627–631
- Thyroid hormones
 - cardiac muscle, nutritional iron deficiency 233–239
- Thyrotoxic periodic paralysis
 - sodium pump 261–264
- Tissue repair
 - lung transplantation 319–327
- Tolerance
 - T-lymphocytes, biliary cirrhosis 551–558
- Total body water
 - chronic kidney failure 763–769
- Total parenteral nutrition
 - neutrophils, sepsis 371–374
- Transforming growth factor
 - blood transfusion 519–523
- Triacylglycerol metabolism
 - creatine supplementation 113–118
- Tryptophan
 - Na⁺, K⁺-ATPase, gestational hypertension 719–723
- Tubular function
 - renal transplant recipients, cyclosporin A 489–496
- Tumour necrosis factor
 - nutrients, inflammation 121–130*
 - pentoxifylline, cirrhosis 29–33
- Tumour suppressor gene
 - nasopharyngeal carcinoma 256–258
- Ultrasound
 - blood flow, vascular disease 17–21
- Urinary bladder
 - calcium antagonist 467–474
- Urine state of saturation
 - calcium nephrolithiasis, mineral water 313–318
- Urogastrone
 - cell proliferation, gastrointestinal tract 503–507
- Vascular disease
 - blood flow, ultrasound 17–21
 - metabolism, amino acids 79–86
- Vascular relaxation
 - sex hormones, menstrual cycle 163–168
- Vascular tone
 - menstrual cycle 163–168
- Vasoconstriction
 - thermoregulation, α -adrenoceptor antagonist 627–631
- Vasodilatation
 - diabetes, dyslipidaemia 567–573
- Vasodilator peptides
 - adrenomedullin 3–16*, 525
- Vasopressin
 - contractile response, octreotide 601–606
- Veins
 - nitric oxide, alcoholic cirrhosis 23–28
- Ventilation
 - almitrine 337–345
- Ventricular pacing
 - natriuretic peptides, neutral endopeptidase 283–291
- Vitamin E
 - antioxidant enzyme, smoking 107–111
 - inflammation, cytokines 121–130*
- White-coat hypertension
 - left ventricular function, echocardiography 275–281
- Wine
 - phenolic compounds, lipoprotein oxidation 449–458
- X-ray absorptiometry
 - chronic kidney failure 763–769
- Zymosan
 - muscle wasting, cytochrome *c* oxidase 475–481